jeudi 1 juin 2017

Onco Actu du 1er juin 2017

1. Biologie

Trouble with CRISPR? Maybe, But Maybe Not [In the Pipeline]

This map will help biologists learn more about the human body than ever before [STAT]

Study Identifies Genetic Mutations in Tumors From 10,000 Patients with Metastatic Cancer [NCI]

2. Etiologie

Lessons from cancer risk in animals [The Darwin Cancer Blog]

4.12 Biopsies liquides

Grail goes global, merges with Hong Kong’s Cirina [FierceBiotech]

As Big Cancer Trials Ramp Up, Grail Goes Global, Merges With Cirina [Xconomy]

GRAIL and Cirina Combine to Create Global Company Focused on Early Detection of Cancer [Grail]

4.2 Dép., diag. & prono. - Génome

In Maine, Making Cancer DNA Tests Free—And Asking Tough Questions [Xconomy]

5. Traitements

Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy [Mass General Hospital]

Technique pinpoints the ‘partners in crime’ of cancer genes [Stanford Medicine]

5.12 Immunothérapies

Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival [AACR]

5.2 Pharma

Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival [Lilly]

Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery [Pfizer]

5.2.1 Pharma - Partenariats

Array adds Ono as Japanese partner for MEK/BRAF combo [FierceBiotech]

5.2.3 Pharma - économie

Merck Ventures leads $11M round in solid tumor startup [FierceBiotech]

Lilly, OrbiMed back China cancer upstart InventisBio in $19M series B [FierceBiotech]

Bicycle Therapeutics Maps Course to Clinic Backed by $52M Investment [Xconomy]

5.3 Traitements - FDA, EMA, NICE...

Regulatory guidance for industry to prepare for the UK’s withdrawal from the EU [EMA]

New action plan to support SMEs as drivers of pharmaceutical innovation [EMA]

5.4 Traitements - Economie

NICE backs Keytruda for first and second-line use [Pharma Times] ASCO (général) - Industriels

AstraZeneca’s ASCO pledge? Be a better social media citizen [FiercePharma]

5.5.10 ASCO (hémato)

Personalized Cell Therapy Combined with Ibrutinib Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients [Penn Medicine]

5.5.4 ASCO (immunothérapies)

Immunotherapy with DNA Vaccine Shows Promise for HPV-Related Head and Neck Cancer [Penn Medicine]

Cancer meeting to provide clues on future immunotherapy combos [Reuters]

5.6 ESMO

ESMO 2017 Media Alert: Integrating Science Into Oncology for a Better Patient Outcome [ESMO]

6. Lutte contre les cancers

ESMO Welcomes the Adoption of the 2017 WHO Cancer Resolution [ESMO]

6.6 Publications

Announcement: Towards greater reproducibility for life-sciences research in Nature [Nature]

6.7 DMP, Big Data & applis

CancerLinQ and NCCN Collaborating to Provide Evidence-Based, Decision-Making Resources to Physicians [ASCO]

6.9 Controverses

UK doctor jailed for 15 years over unnecessary breast surgery [Reuters]